ADC Therapeutics Net Income Over Time
| ADCT Stock | USD 3.90 0.29 8.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ADC Therapeutics Performance and ADC Therapeutics Correlation. Is there potential for Communications Equipment market expansion? Will ADC introduce new products? Factors like these will boost the valuation of ADC Therapeutics. If investors know ADC will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about ADC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
Understanding ADC Therapeutics requires distinguishing between market price and book value, where the latter reflects ADC's accounting equity. The concept of intrinsic value—what ADC Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push ADC Therapeutics' price substantially above or below its fundamental value.
Understanding that ADC Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADC Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ADC Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare ADC Therapeutics and related stocks such as Omeros, Neumora Therapeutics, and RAPT Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OMER | (7.4 M) | (28.5 M) | (38.4 M) | (39.8 M) | (73.7 M) | (75.1 M) | (66.7 M) | (53.5 M) | (126.8 M) | (84.5 M) | (138.1 M) | (111.4 M) | 47.4 M | (117.8 M) | (156.8 M) | (141.1 M) | (134.1 M) |
| NMRA | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (99.3 M) | (237.3 M) | (130.9 M) | (235.9 M) | (243.8 M) | (219.4 M) | (230.4 M) |
| RAPT | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (36.1 M) | (43 M) | (52.9 M) | (68.2 M) | (81.9 M) | (116.8 M) | (129.9 M) | (116.9 M) | (111 M) |
| AUTL | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (7.5 M) | (12.6 M) | (19.7 M) | (31.1 M) | (123.8 M) | (142.1 M) | (142.1 M) | (148.8 M) | (208.4 M) | (220.7 M) | (198.6 M) | (188.7 M) |
| ALMS | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (111.9 M) | (155 M) | (294.2 M) | (264.8 M) | (278.1 M) |
| BCYC | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (16.3 M) | (21.8 M) | (30.6 M) | (51 M) | (66.8 M) | (112.7 M) | (180.7 M) | (169 M) | (152.1 M) | (144.5 M) |
| LXRX | (12.5 M) | (116.2 M) | (110.2 M) | (104.1 M) | (100.3 M) | (4.7 M) | (141.4 M) | (129.1 M) | (120.5 M) | 130.1 M | (58.6 M) | (87.8 M) | (101.9 M) | (177.1 M) | (200.4 M) | (180.4 M) | (171.3 M) |
| FDMT | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (9.6 M) | (49.3 M) | (56.7 M) | (68.3 M) | (101.1 M) | (100.8 M) | (160.9 M) | (144.8 M) | (137.5 M) |
| LCTX | (700 K) | (16.5 M) | (21.4 M) | (43.9 M) | (36.4 M) | (47 M) | 33.6 M | (20 M) | (46 M) | (11.7 M) | (20.6 M) | (43 M) | (26.3 M) | (21.5 M) | (18.6 M) | (16.7 M) | (17.6 M) |
| QSI | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (36.6 M) | (95 M) | (132.4 M) | (96 M) | (101 M) | (90.9 M) | (95.5 M) |
ADC Therapeutics and related stocks such as Omeros, Neumora Therapeutics, and RAPT Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in ADC Therapeutics financial statement analysis. It represents the amount of money remaining after all of ADC Therapeutics SA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| ADC Therapeutics SA | ADCT |
Specialization | Information Technology, Technology Hardware & Equipment |
| Business Address | BiopOle, Epalinges, Switzerland, |
| Exchange | New York Stock Exchange |
USD 3.9
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.